1 December 2011
Possible Alteration of Amyloid-β Protein Precursor Metabolism or Trafficking in a 17β-Hydroxysteroid Dehydrogenase X Deficiency Patient
We read with great interest the recent report by Ortez et al. , “Undetectable levels of CSF amyloid-β (Aβ) peptide in a patient with 17β-hydroxysteroid dehydrogenase deficiency”. The authors claim that Aβ peptide was not detectable in the cerebrospinal fluid (CSF) of a mentally retarded patient. The dramatically reduced levels of amyloid-β peptide in CSF might indicate an alteration of amyloid-β protein precursor metabolism or trafficking in the patient’s brain.
1 November 2011
There has been extensive media coverage recently of the findings of Luengo-Fernandez et al. (2011). Dementia is indeed a costly condition. But, from examining the Supplementary Data (http://www.j-alz.com/issues/27/luengo_supplement.pdf), is it possible that the cost has been over-estimated?
1 October 2011
Critical for the increasing prevalence of Alzheimer’s disease and mild cognitive impairment are treatments that modify disease progression rather than providing only symptomatic benefit.
1 August 2011
I read with interest a recent article by Chen et al.  in the Journal of Alzheimer’s Disease (JAD) where the authors review various concepts relating to the possible cause of Alzheimer’s disease (AD). In that paper, Dr. Chen states: “Thus, put together we propose that advanced aging plus risk factors best explain most SD (senile dementia) cases (4)”. That reference “(4)” cites Dr. Chen’s previous paper from Frontiers in Bioscience published in 2001. In that Frontiers article, Dr.
1 May 2011
We have read with interest the paper of Lescai et al. We were quite surprised by the lack of any reference to a previous study of Bizzarro et al., already reporting these results. In a relative large sample of AD cases from Central and Southern Italy Bizzarro et al. observed a significant association of the -219 (rs405509) polymorphism with AD. Similar, an association of the -219/e4 haplotypes with AD was also reported. Therefore, the study of Lescai et al.
1 February 2011
Could a Combination of the Clock Drawing Test and the Mini-Mental Status Examination Be Used to Screen Dementia in a Neurological Setting? Comments with Data from the NEDICES Survey
The interesting paper recently presented in the Journal of Alzheimer’s Disease  suggests, in agreement with one recent report , a utilization of the clock drawing test (CDT), in combination with the Mini-Mental Status Examination (MMSE), as a screening method for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in a neurological setting. This is a relatively new use of the CDT and MMSE, because both tests are traditionally and preferably employed in these disorders in population- and community-based surveys .
1 December 2010
The article by Walton  indicated aluminum is instrumental in causing hyperphosphorylation of tau with subsequent development of neurofibrillary tangle formation. Recently tau has been found to mislocalize to dendritic spines causing early synaptic dysfunction . Aluminum mediated hyperphosphorylation of tau may be a trigger for tau dysfunction and abnormal cellular trafficking with mislocalization to dendrites causing synaptic dysfunction, which probably is an early feature of Alzheimer's disease.
1 May 2010
We thank Dr. Kumlin and colleagues for their insightful comments regarding our paper . Inasmuch as we were unaware of their earlier study involving EMF exposure to normal rats , we did not include it among the references in our paper and apologize for this oversight. Kumlin et al.  did indeed provide initial evidence that long-term EMF exposure (2 hrs/day, 5 days/week, for 5 weeks) can improve cognitive performance in rodents. It is important to note, however, that they provided EMF exposure to very young rats from 3-8 weeks of age.
1 May 2010
We note that Perucho et al.  cite (reference number 28) a 2007 publication by Pravat K Mandal , and we wish to point out to the authors and your readers that the Biochemistry paper in question was retracted later that same year , as was another article by Mandal , because “the anesthetic concentration of our paper[s] was misrepresented”. Those papers should therefore not be cited as evidence.
1 April 2010
In a recent issue of Journal of Alzheimer’s Disease, Zhang and colleagues presented interesting data concerning the cholinergic deficit in Alzheimer’s disease (AD) . These results demonstrated decreases in the activity of acetylcholinesterase (AChE) and reduced mRNA levels of α4 and β2 nicotinic acetylcholine receptor (nAChR) subunits in peripheral blood of patients with AD in an elderly Chinese population.